|
Jul 29
|
Rapid Expansion and Innovation Drive $36 Billion Global Point-of-Care Diagnostics Market, Says New Kalorama Report
|
|
Jul 29
|
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
|
|
Jul 29
|
Tempus AI Taps Growing ICI Market With New xM Assay
|
|
Jul 28
|
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
|
|
Jul 28
|
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards?
|
|
Jul 25
|
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
|
|
Jul 25
|
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?
|
|
Jul 25
|
3 Reasons EXAS is Risky and 1 Stock to Buy Instead
|
|
Jul 24
|
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
|
|
Jul 24
|
Why Exact Sciences (EXAS) is a Top Growth Stock for the Long-Term
|
|
Jul 24
|
SubjectWell Appoints Veteran Healthcare Finance Leader Karl Stubelis as Chief Financial Officer
|
|
Jul 18
|
Thermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know
|
|
Jul 16
|
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
|
|
Jul 15
|
Wall Street Analysts Think Exact Sciences (EXAS) Could Surge 26.24%: Read This Before Placing a Bet
|
|
Jul 15
|
Tempus AI Raises 2025 Financial Outlook: What's Backing It?
|
|
Jul 14
|
Exact Sciences Schedules Second Quarter 2025 Earnings Call
|
|
Jul 14
|
1 Healthcare Stock for Long-Term Investors and 2 to Be Wary Of
|
|
Jul 10
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Jul 10
|
QGEN or EXAS: Which Is the Better Value Stock Right Now?
|
|
Jul 9
|
Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer
|